for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Emergent Biosolutions Inc

EBS.N

Latest Trade

56.02USD

Change

-2.09(-3.60%)

Volume

92,863

Today's Range

55.84

 - 

58.59

52 Week Range

39.11

 - 

67.00

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Emergent BioSolutions Reports Third Quarter Results

Nov 6 (Reuters) - Emergent BioSolutions Inc <EBS.N>::EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2019.Q3 ADJUSTED EARNINGS PER SHARE $1.21.Q3 EARNINGS PER SHARE $0.83.Q3 REVENUE $311.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $289.3 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $0.90 -- REFINITIV IBES DATA.FULL YEAR 2019 FINANCIAL FORECAST REAFFIRMED.

Emergent Biosolutions Receives EMA Prime Designation For Its Chikungunya Virus Vlp Vaccine Candidate

Oct 10 (Reuters) - Emergent BioSolutions Inc <EBS.N>::EMERGENT BIOSOLUTIONS RECEIVES EMA PRIME DESIGNATION FOR ITS CHIKUNGUNYA VIRUS VLP VACCINE CANDIDATE.EMERGENT BIOSOLUTIONS INC - CONTEMPLATES INITIATION OF A PIVOTAL TRIAL FOR CHIKUNGUNYA VACCINE CANDIDATE IN 2020.

Emergent BioSolutions Awarded 10-Year HHS Contract to Deliver ACAM2000 Into the Strategic National Stockpile

Sept 3 (Reuters) - Emergent BioSolutions Inc <EBS.N>::EMERGENT BIOSOLUTIONS AWARDED 10-YEAR HHS CONTRACT TO DELIVER ACAM2000®, (SMALLPOX (VACCINIA) VACCINE, LIVE) INTO THE STRATEGIC NATIONAL STOCKPILE.EMERGENT BIOSOLUTIONS - CONTRACT AWARD VALUED AT ABOUT $2 BILLION OVER 10 YEARS FOR CONTINUED SUPPLY OF ACAM2000 INTO U.S. STRATEGIC NATIONAL STOCKPILE.EMERGENT BIOSOLUTIONS INC - COMPANY EXPECTS TO DELIVER INTO SNS A MAJORITY OF DOSES UNDER BASE YEAR BY YEAR END 2019.

Emergent Biosolutions Posts Q2 Loss Per Share Of $0.18

Aug 1 (Reuters) - Emergent BioSolutions Inc <EBS.N>::EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2019.Q2 ADJUSTED LOSS PER SHARE $0.12.Q2 LOSS PER SHARE $0.18.Q2 REVENUE $243.2 MILLION VERSUS REFINITIV IBES ESTIMATE OF $212.1 MILLION.SEES Q3 2019 REVENUE $245 MILLION TO $275 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $0.17 -- REFINITIV IBES DATA.REAFFIRMS FULL YEAR 2019 FINANCIAL FORECAST AND OPERATIONAL GOALS.Q3 REVENUE VIEW $289.0 MILLION -- REFINITIV IBES DATA.

Emergent Announces FDA Approval Of Change In Storage Conditions And Transfer Of Manufacturing For Its Cholera Vaccine

June 4 (Reuters) - Emergent BioSolutions Inc <EBS.N>::EMERGENT BIOSOLUTIONS ANNOUNCES FDA APPROVAL OF CHANGE IN STORAGE CONDITIONS AND TRANSFER OF MANUFACTURING FOR ITS CHOLERA VACCINE.EMERGENT BIOSOLUTIONS - ANNOUNCED APPROVAL BY FDA OF PRIOR APPROVAL SUPPLEMENT SUBMITTED BY CO FOR ITS ORAL CHOLERA VACCINE, VAXCHORA.EMERGENT BIOSOLUTIONS - VAXCHORA PRIOR APPROVAL SUPPLEMENT SUPPORTS CHANGE IN STORAGE CONDITIONS OF THE VACCINE FROM FROZEN TO REFRIGERATED AT 2-8°C.EMERGENT BIOSOLUTIONS - VAXCHORA PRIOR APPROVAL SUPPLEMENT SUPPORTS TRANSFER OF THE BULK DRUG SUBSTANCE MANUFACTURING TO MANUFACTURING FACILITY IN BERN.

Emergent Biosolutions Reports Q1 Adjusted Loss Per Share $0.13

May 2 (Reuters) - Emergent BioSolutions Inc <EBS.N>::EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 ADJUSTED LOSS PER SHARE $0.13.Q1 LOSS PER SHARE $0.51.Q1 REVENUE $190.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $201.2 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $0.09 -- REFINITIV IBES DATA.SEES Q2 2019 REVENUE $200 MILLION TO $220 MILLION.PROVIDES Q2 2019 REVENUE FORECAST OF $200M-$220M.FOR FY 2019, COMPANY REAFFIRMS ITS EXPECTATION OF TOTAL REVENUES, NET INCOME, ADJUSTED NET INCOME, EBITDA, ADJUSTED EBITDA.Q2 REVENUE VIEW $254.1 MILLION -- REFINITIV IBES DATA.

Emergent Biosolutions Reports Interim Results From Phase 2 Study Evaluating Its Chikungunya Virus Vaccine Candidate

April 16 (Reuters) - Emergent BioSolutions Inc <EBS.N>::EMERGENT BIOSOLUTIONS ANNOUNCES INTERIM RESULTS FROM PHASE 2 STUDY EVALUATING CHIKV-VLP, CHIKUNGUNYA VIRUS VACCINE CANDIDATE.EMERGENT BIOSOLUTIONS - UP TO 98% OF STUDY PARTICIPANTS PRODUCED A NEUTRALIZING ANTIBODY RESPONSE AGAINST CHIKUNGUNYA VIRUS (CHIKV) BY DAY 7.EMERGENT BIOSOLUTIONS INC - VACCINE CANDIDATE WAS WELL-TOLERATED ACROSS ALL STUDY ARMS.EMERGENT BIOSOLUTIONS INC - NO SIGNIFICANT VACCINE-RELATED SAFETY CONCERNS HAVE BEEN IDENTIFIED IN ANALYSES TO DATE.

Emergent Biosolutions Awarded U.S. Department Of State Contract To Supply Medical Countermeasures For Chemical Warfare Agents

Feb 28 (Reuters) - Emergent BioSolutions Inc <EBS.N>::EMERGENT BIOSOLUTIONS AWARDED U.S. DEPARTMENT OF STATE CONTRACT TO SUPPLY MEDICAL COUNTERMEASURES FOR CHEMICAL WARFARE AGENTS.EMERGENT BIOSOLUTIONS INC - TOTAL CONTRACT VALUE OF A MINIMUM OF APPROXIMATELY $7 MILLION TO A MAXIMUM OF $100 MILLION OVER CONTRACT'S PERIOD OF PERFORMANCE.EMERGENT BIOSOLUTIONS INC - CONTRACT IS COMPRISED OF A FIVE-YEAR BASE PERIOD OF PERFORMANCE ALONG WITH FIVE ONE-YEAR OPTION PERIODS.

Emergent Biosolutions Reports Fourth Quarter And Full Year 2018 Financial Results

Feb 21 (Reuters) - Emergent BioSolutions Inc <EBS.N>::EMERGENT BIOSOLUTIONS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 ADJUSTED EARNINGS PER SHARE $0.75.Q4 LOSS PER SHARE $0.07.Q4 REVENUE $270.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $270 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $0.65 -- REFINITIV IBES DATA.SEES Q1 2019 REVENUE $185 MILLION TO $205 MILLION.FOR FULL YEAR 2019, COMPANY REAFFIRMS ITS EXPECTATION.

Emergent Biosolutions Announces Appointment Of Robert Kramer, Sr. To Its Board

Jan 24 (Reuters) - Emergent BioSolutions Inc <EBS.N>::EMERGENT BIOSOLUTIONS ANNOUNCES APPOINTMENT OF ROBERT G. KRAMER, SR. TO ITS BOARD OF DIRECTORS.EMERGENT BIOSOLUTIONS -ROBERT KRAMER WILL ASSUME ROLE OF PRESIDENT AND CEO AND WILL SERVE ON THE EMERGENT BOARD, SUCCEEDING DANIEL J. ABDUN-NABI.EMERGENT BIOSOLUTIONS INC SAYS ROBERT KRAMER WILL ASSUME ROLE OF PRESIDENT AND CEO EFFECTIVE APRIL 1, 2019.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up